RxGrab · Drug pricing tool · CMS NADAC and FDA Orange Book read 2026-11-12
Try one
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page year-end surveys and the Orange Book data files, read 2026-11-12.
You read the cliff as a median with a wide band around it, not as a rule.
The median generic keeps getting cheaper for about ten years after the first generic approval, fastest in the first five.
| Years since first generic approval | Median | Middle half | Products |
|---|---|---|---|
| 0 | 100% | 100% to 100% | 79 |
| 1 | 95% | 71% to 100% | 118 |
| 2 | 80% | 49% to 99% | 135 |
| 3 | 64% | 36% to 90% | 142 |
| 4 | 55% | 25% to 84% | 154 |
| 5 | 46% | 16% to 80% | 154 |
| 6 | 45% | 16% to 87% | 154 |
| 7 | 40% | 14% to 71% | 153 |
| 8 | 32% | 8% to 65% | 131 |
| 9 | 28% | 7% to 67% | 109 |
| 10 | 22% | 5% to 53% | 90 |
| 11 | 21% | 5% to 51% | 79 |
| 12 | 16% | 6% to 34% | 48 |
| 13 | 19% | 14% to 39% | 23 |
200 matched products. A year is shown only where 20 or more products contribute. Index of the year-end median per-unit acquisition cost to its first observed year-end price at or after the first generic approval.
The most common mistake reads the median as a forecast for one drug. Individual drugs sit far above and below it.
"The curve says my generic will cost half as much in five years."
Read the band, not the line: after five years the middle half of drugs runs from 16% to 80%. Add your drug to see its own path, and see the FDA generic drug facts for how generics are approved.
The curve can be shown on another site as a self-sizing panel, free with the source line left in place.
<div data-generic-price-cliff></div>
<script async src="https://rxgrab.com/tools/generic-price-cliff/embed.js"></script>
Across 200 matched tablet and capsule generics, the median acquisition cost is 80% of its first observed year-end price two years after the first generic approval, 46% after five years and 22% after ten. The spread between drugs is wide: after ten years the middle half runs from 5% to 53%.
This page does not say so. It describes the pattern in the matched products. Competition, supply, rebates and changes in what is priced all move acquisition costs, and the data does not separate them.
No one can say that from this page. The curve is the median of matched products and individual drugs sit far above and below it. Type your drug to see its own path beside the median.
No. NADAC is the price pharmacies pay to acquire a drug. What you pay adds a dispensing fee and margin and depends on your plan or card.
A drug is included when it is a generic tablet or capsule that matches one single-ingredient Orange Book group with a dated first brand and first generic approval from 2013 to 2022, and has at least three year-end surveys after that. Injectables, liquids, combinations and older drugs are not included, so the curve describes a minority of products.
The CMS National Average Drug Acquisition Cost year-end surveys and the FDA Orange Book data files, read 2026-11-12. Both are public US government data.
Yes. The embed code on this page shows the curve as a self-sizing panel, free to use with the source line left in place.
The cliff joins two public datasets, each with its own frozen method, under a third frozen method written before any figure was published. A separate reader rebuilt the matched product set and the whole curve from the raw snapshot rows and the raw Orange Book files; its first run found a matching defect in the builder (a single-ingredient drug matched to a three-drug combination), which is recorded as a dated amendment, and after the fix the two agree on all 200 products and every year of the curve. What the independent check found. The dataset behind it is published at doi:10.5281/zenodo.24182324. Further reading: the CMS pharmacy pricing page; the CMS open data portal; the FDA Orange Book; the Orange Book data files; how generic drugs are approved; the FDA generic drug facts; the FDA first generic approvals; 42 CFR 447.512 on drug payment; the FTC on pharmaceutical competition; the Congressional Budget Office on health care; the NLM RxNav drug names service.